Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,338

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Gout

Dalbeth, Nicola, Gosling, Anna L, Gaffo, Angelo, Abhishek, Abhishek·2021·The Lancet
DOI 10.1016/s0140-6736(21)00569-9
Open this paper in CoChat — free account

Abstract

Gout is a common and treatable disease caused by the deposition of monosodium urate crystals in articular and non-articular structures. Increased concentration of serum urate (hyperuricaemia) is the most important risk factor for the development of gout. Serum urate is regulated by urate transporters in the kidney and gut, particularly GLUT9 (SLC2A9), URAT1 (SLC22A12), and ABCG2. Activation of the NLRP3 inflammasome by monosodium urate crystals with release of IL-1β plays a major role in the initiation of the gout flare; aggregated neutrophil extracellular traps are important in the resolution phase. Although presenting as an intermittent flaring condition, gout is a chronic disease. Long-term urate lowering therapy (eg, allopurinol) leads to the dissolution of monosodium urate crystals, ultimately resulting in the prevention of gout flares and tophi and in improved quality of life. Strategies such as nurse-led care are effective in delivering high-quality gout care and lead to major improvements in patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00569-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 151

  1. Taylor, 2015, Study for updated gout classification criteria: identification of features to classify gout, Arthritis Care Res (Hoboken), 67, 1304, 10.1002/acr.22585 · DOI
  2. Singh, 2017, Gout self-management in African American Veterans: a qualitative exploration of challenges and solutions from patients' perspectives, Arthritis Care Res (Hoboken), 69, 1724, 10.1002/acr.23202 · DOI
  3. Gaffo, 2012, Developing a provisional definition of flare in patients with established gout, Arthritis Rheum, 64, 1508, 10.1002/art.33483 · DOI
  4. Bursill, 2019, Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout, Arthritis Care Res (Hoboken), 71, 427, 10.1002/acr.23607 · doi:10.1002/acr.23607
  5. Toprover, 2015, Gout in the spine: imaging, diagnosis, and outcomes, Curr Rheumatol Rep, 17, 70, 10.1007/s11926-015-0547-7 · doi:10.1007/s11926-015-0547-7
  6. Ho, 1993, Gout and pseudogout in hospitalized patients, Arch Intern Med, 153, 2787, 10.1001/archinte.1993.00410240099012 · doi:10.1001/archinte.1993.00410240099012
  7. Shiozawa, 2017, Serum uric acid and the risk of incident and recurrent gout: a systematic review, J Rheumatol, 44, 388, 10.3899/jrheum.160452 · doi:10.3899/jrheum.160452
  8. Zhang, 2012, Purine-rich foods intake and recurrent gout attacks, Ann Rheum Dis, 71, 1448, 10.1136/annrheumdis-2011-201215 · DOI
  9. Zhang, 2006, Alcohol consumption as a trigger of recurrent gout attacks, Am J Med, 119, 800.e13, 10.1016/j.amjmed.2006.01.020 · DOI
  10. Dubreuil, 2013, Increased risk of recurrent gout attacks with hospitalization, Am J Med, 126, 1138, 10.1016/j.amjmed.2013.06.026 · doi:10.1016/j.amjmed.2013.06.026
  11. Rothenbacher, 2011, Frequency and risk factors of gout flares in a large population-based cohort of incident gout, Rheumatology (Oxford), 50, 973, 10.1093/rheumatology/keq363 · DOI
  12. Bieber, 2018, Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature, Semin Arthritis Rheum, 47, 843, 10.1016/j.semarthrit.2017.11.006 · doi:10.1016/j.semarthrit.2017.11.006
  13. Gutman, 1973, The past four decades of progress in the knowledge of gout, with an assessment of the present status, Arthritis Rheum, 16, 431, 10.1002/art.1780160402 · doi:10.1002/art.1780160402
  14. Neogi, 2015, 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 74, 1789, 10.1136/annrheumdis-2015-208237 · DOI · Paper page
  15. Aati, 2014, Toward development of a Tophus Impact Questionnaire: a qualitative study exploring the experience of people with tophaceous gout, J Clin Rheumatol, 20, 251, 10.1097/RHU.0000000000000127 · doi:10.1097/rhu.0000000000000127
  16. Bevis, 2018, Comorbidity clusters in people with gout: an observational cohort study with linked medical record review, Rheumatology (Oxford), 57, 1358, 10.1093/rheumatology/key096 · doi:10.1093/rheumatology/key096
  17. Dehlin, 2016, Incidence and prevalence of gout in Western Sweden, Arthritis Res Ther, 18, 164, 10.1186/s13075-016-1062-6 · doi:10.1186/s13075-016-1062-6
  18. Rai, 2017, The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012, Semin Arthritis Rheum, 46, 451, 10.1016/j.semarthrit.2016.08.006 · DOI
  19. Richette, 2015, Revisiting comorbidities in gout: a cluster analysis, Ann Rheum Dis, 74, 142, 10.1136/annrheumdis-2013-203779 · DOI
  20. Perez-Ruiz, 2014, Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout, Ann Rheum Dis, 73, 177, 10.1136/annrheumdis-2012-202421 · DOI
  21. Zhu, 2012, Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008, Am J Med, 125, 679, 10.1016/j.amjmed.2011.09.033 · DOI · Paper page
  22. Fisher, 2017, The unclosing premature mortality gap in gout: a general population-based study, Ann Rheum Dis, 76, 1289, 10.1136/annrheumdis-2016-210588 · DOI
  23. Kim, 2017, Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015, Rheumatol Int, 37, 1499, 10.1007/s00296-017-3768-4 · DOI
  24. Kuo, 2015, Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study, Ann Rheum Dis, 74, 661, 10.1136/annrheumdis-2013-204463 · DOI · Paper page
  25. Zobbe, 2019, Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study, Rheumatology (Oxford), 58, 836, 10.1093/rheumatology/key390 · DOI
  26. Chen-Xu, 2019, Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007–2016, Arthritis Rheumatol, 71, 991, 10.1002/art.40807 · DOI · Paper page
  27. Kuo, 2015, Global epidemiology of gout: prevalence, incidence and risk factors, Nat Rev Rheumatol, 11, 649, 10.1038/nrrheum.2015.91 · DOI · Paper page
  28. Gosling, 2014, Hyperuricaemia in the Pacific: why the elevated serum urate levels?, Rheumatol Int, 34, 743, 10.1007/s00296-013-2922-x · DOI
  29. Dalbeth, 2018, Gout in Aotearoa New Zealand: the equity crisis continues in plain sight, N Z Med J, 131, 8
  30. Dalbeth, 2013, The experience and impact of gout in Māori and Pacific people: a prospective observational study, Clin Rheumatol, 32, 247, 10.1007/s10067-012-2110-5 · doi:10.1007/s10067-012-2110-5
  31. Hak, 2010, Menopause, postmenopausal hormone use and risk of incident gout, Ann Rheum Dis, 69, 1305, 10.1136/ard.2009.109884 · DOI
  32. Drivelegka, 2018, Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy, Arthritis Res Ther, 20, 108, 10.1186/s13075-018-1596-x · doi:10.1186/s13075-018-1596-x
  33. Campion, 1987, Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study, Am J Med, 82, 421, 10.1016/0002-9343(87)90441-4 · DOI · Paper page
  34. Choi, 2004, Purine-rich foods, dairy and protein intake, and the risk of gout in men, N Engl J Med, 350, 1093, 10.1056/NEJMoa035700 · DOI · Paper page
  35. Choi, 2004, Alcohol intake and risk of incident gout in men: a prospective study, Lancet, 363, 1277, 10.1016/S0140-6736(04)16000-5 · DOI · Paper page
  36. Tin, 2019, Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels, Nat Genet, 51, 1459, 10.1038/s41588-019-0504-x · DOI · Paper page
  37. Major, 2018, Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts, BMJ, 363
  38. Dalbeth, 2014, Hyperuricaemia and gout: time for a new staging system?, Ann Rheum Dis, 73, 1598, 10.1136/annrheumdis-2014-205304 · DOI
  39. Han, 2014, Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease, BMC Nephrol, 15, 63, 10.1186/1471-2369-15-63 · doi:10.1186/1471-2369-15-63
  40. Facchini, 1991, Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration, JAMA, 266, 3008, 10.1001/jama.1991.03470210076036 · DOI · Paper page
  41. Yü, 1981, Effects of diuretics on urate and calcium excretion, Arch Intern Med, 141, 915, 10.1001/archinte.1981.00340070095019 · doi:10.1001/archinte.1981.00340070095019
  42. Bahn, 2008, Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13), J Biol Chem, 283, 16332, 10.1074/jbc.M800737200 · DOI · Paper page
  43. Vitart, 2008, SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout, Nat Genet, 40, 437, 10.1038/ng.106 · DOI · Paper page
  44. Enomoto, 2002, Molecular identification of a renal urate anion exchanger that regulates blood urate levels, Nature, 417, 447, 10.1038/nature742 · DOI · Paper page
  45. Ekaratanawong, 2004, Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules, J Pharmacol Sci, 94, 297, 10.1254/jphs.94.297 · DOI
  46. Chiba, 2015, NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout, Arthritis Rheumatol, 67, 281, 10.1002/art.38884 · DOI
  47. Van Aubel, 2005, Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites, Am J Physiol Renal Physiol, 288, F327, 10.1152/ajprenal.00133.2004 · DOI
  48. Woodward, 2009, Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout, Proc Natl Acad Sci USA, 106, 10338, 10.1073/pnas.0901249106 · DOI · Paper page
  49. Bakhiya, 2003, Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux, Cell Physiol Biochem, 13, 249, 10.1159/000074539 · DOI
  50. Kimura, 2014, Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells, PloS One, 9, 10.1371/journal.pone.0084996 · doi:10.1371/journal.pone.0084996
  51. Ichida, 2012, Decreased extra-renal urate excretion is a common cause of hyperuricemia, Nat Commun, 3, 764, 10.1038/ncomms1756 · DOI · Paper page
  52. Xu, 2016, Uric acid transporters hiding in the intestine, Pharm Biol, 54, 3151, 10.1080/13880209.2016.1195847 · DOI
  53. Köttgen, 2013, Genome-wide association analyses identify 18 new loci associated with serum urate concentrations, Nat Genet, 45, 145, 10.1038/ng.2500 · DOI · Paper page
  54. Dalbeth, 2018, Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis, Ann Rheum Dis, 77, 1048, 10.1136/annrheumdis-2017-212288 · doi:10.1136/annrheumdis-2017-212288
  55. Howard, 2011, Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers, Arthritis Care Res (Hoboken), 63, 1456, 10.1002/acr.20527 · doi:10.1002/acr.20527
  56. Dalbeth, 2015, Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study, Ann Rheum Dis, 74, 908, 10.1136/annrheumdis-2014-206397 · DOI
  57. Chhana, 2019, Human cartilage homogenates influence the crystallization of monosodium urate and inflammatory response to monosodium urate crystals: a potential link between osteoarthritis and gout, Arthritis Rheumatol, 71, 2090, 10.1002/art.41038 · doi:10.1002/art.41038
  58. Loeb, 1972, The influence of temperature on the solubility of monosodium urate, Arthritis Rheum, 15, 189, 10.1002/art.1780150209 · DOI · Paper page
  59. Chhana, 2015, Factors influencing the crystallization of monosodium urate: a systematic literature review, BMC Musculoskelet Disord, 16, 296, 10.1186/s12891-015-0762-4 · doi:10.1186/s12891-015-0762-4
  60. Liu-Bryan, 2005, Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation, Arthritis Rheum, 52, 2936, 10.1002/art.21238 · DOI · Paper page
  61. Bauernfeind, 2009, Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, J Immunol, 183, 787, 10.4049/jimmunol.0901363 · DOI · Paper page
  62. Pascual, 1999, Synovial fluid analysis for diagnosis of intercritical gout, Ann Intern Med, 131, 756, 10.7326/0003-4819-131-10-199911160-00007 · DOI
  63. De Miguel, 2012, Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study, Ann Rheum Dis, 71, 157, 10.1136/ard.2011.154997 · doi:10.1136/ard.2011.154997
  64. Joosten, 2010, Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis, Arthritis Rheum, 62, 3237, 10.1002/art.27667 · DOI · Paper page
  65. Yokose, 2019, Risk of gout flares after vaccination: a prospective case cross-over study, Ann Rheum Dis, 78, 1601, 10.1136/annrheumdis-2019-215724 · DOI
  66. Vieira, 2015, A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout, Arthritis Rheumatol, 67, 1646, 10.1002/art.39107 · DOI · Paper page
  67. Wang, 2016, AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages, Ann Rheum Dis, 75, 286, 10.1136/annrheumdis-2014-206074 · DOI
  68. Schauer, 2014, Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines, Nat Med, 20, 511, 10.1038/nm.3547 · DOI · Paper page
  69. Chen, 2011, Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3, Ann Rheum Dis, 70, 1655, 10.1136/ard.2010.145821 · DOI
  70. Liu, 2016, Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout, Arthritis Res Ther, 18, 268, 10.1186/s13075-016-1167-y · DOI
  71. Palmer, 1989, Development of the gout tophus. An hypothesis, Am J Clin Pathol, 91, 190, 10.1093/ajcp/91.2.190 · doi:10.1093/ajcp/91.2.190
  72. Dalbeth, 2010, Cellular characterization of the gouty tophus: a quantitative analysis, Arthritis Rheum, 62, 1549, 10.1002/art.27356 · DOI · Paper page
  73. Dalbeth, 2009, Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography, Ann Rheum Dis, 68, 1290, 10.1136/ard.2008.094201 · DOI
  74. Dalbeth, 2008, Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells, Arthritis Rheum, 58, 1854, 10.1002/art.23488 · DOI
  75. Chhana, 2011, Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout, Ann Rheum Dis, 70, 1684, 10.1136/ard.2010.144774 · DOI
  76. Chhana, 2018, Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state, Arthritis Res Ther, 20, 208, 10.1186/s13075-018-1704-y · DOI
  77. Poh, 2011, Magnetic resonance imaging bone edema is not a major feature of gout unless there is concomitant osteomyelitis: 10-year findings from a high-prevalence population, J Rheumatol, 38, 2475, 10.3899/jrheum.110477 · DOI
  78. Gui, 2018, Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital-based cross-sectional study, An Bras Dermatol, 93, 761, 10.1590/abd1806-4841.20187547 · doi:10.1590/abd1806-4841.20187547
  79. Felten, 2020, At the crossroads of gout and psoriatic arthritis: “psout”, Clin Rheumatol, 39, 1405, 10.1007/s10067-020-04981-0 · DOI
  80. Roddy, 2007, Are joints affected by gout also affected by osteoarthritis?, Ann Rheum Dis, 66, 1374, 10.1136/ard.2006.063768 · DOI
  81. Paul, 1983, Morphological characteristics of monosodium urate: a transmission electron microscopic study of intact natural and synthetic crystals, Ann Rheum Dis, 42, 75, 10.1136/ard.42.1.75 · doi:10.1136/ard.42.1.75
  82. Janssens, 2010, A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis, Arch Intern Med, 170, 1120, 10.1001/archinternmed.2010.196 · DOI · Paper page
  83. Urano, 2002, The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis, J Rheumatol, 29, 1950
  84. Zhao, 2018, Renal excretion is a cause of decreased serum uric acid during acute gout, Int J Rheum Dis, 21, 1723, 10.1111/1756-185X.13348 · doi:10.1111/1756-185x.13348
  85. Lee, 2017, Diagnostic accuracy of dual-energy computed tomography in patients with gout: a meta-analysis, Semin Arthritis Rheum, 47, 95, 10.1016/j.semarthrit.2017.03.002 · DOI
  86. Lee, 2018, Diagnostic accuracy of ultrasound in patients with gout: a meta-analysis, Semin Arthritis Rheum, 47, 703, 10.1016/j.semarthrit.2017.09.012 · DOI
  87. Roddy, 2020, Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care, Ann Rheum Dis, 79, 276, 10.1136/annrheumdis-2019-216154 · DOI
  88. Rainer, 2016, Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial, Ann Intern Med, 164, 464, 10.7326/M14-2070 · DOI
  89. Man, 2007, Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial, Ann Emerg Med, 49, 670, 10.1016/j.annemergmed.2006.11.014 · DOI
  90. Janssens, 2008, Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial, Lancet, 371, 1854, 10.1016/S0140-6736(08)60799-0 · DOI · Paper page
  91. Terkeltaub, 2010, High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study, Arthritis Rheum, 62, 1060, 10.1002/art.27327 · DOI · Paper page
  92. Qaseem, 2017, Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians, Ann Intern Med, 166, 58, 10.7326/M16-0570 · DOI · Paper page
  93. Richette, 2017, 2016 updated EULAR evidence-based recommendations for the management of gout, Ann Rheum Dis, 76, 29, 10.1136/annrheumdis-2016-209707 · DOI · Paper page
  94. Terkeltaub, 2011, Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors, Arthritis Rheum, 63, 2226, 10.1002/art.30389 · DOI
  95. Fernández, 1999, Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide, J Rheumatol, 26, 2285
  96. Schlesinger, 2012, Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions, Ann Rheum Dis, 71, 1839, 10.1136/annrheumdis-2011-200908 · DOI · Paper page
  97. Janssen, 2019, Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial, Rheumatology (Oxford), 58, 1344, 10.1093/rheumatology/key402 · DOI
  98. Schlesinger, 2002, Local ice therapy during bouts of acute gouty arthritis, J Rheumatol, 29, 331
  99. FitzGerald, 2020, 2020 American College of Rheumatology guideline for the management of gout, Arthritis Rheumatol, 72, 879, 10.1002/art.41247 · DOI · Paper page
  100. Dalbeth, 2019, Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial, Arthritis Rheumatol, 71, 1739, 10.1002/art.40929 · doi:10.1002/art.40929
  101. Dalbeth, 2017, Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study, Arthritis Rheumatol, 69, 2386, 10.1002/art.40233 · DOI
  102. Doherty, 2018, Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial, Lancet, 392, 1403, 10.1016/S0140-6736(18)32158-5 · DOI · Paper page
  103. Hill, 2015, Does starting allopurinol prolong acute treated gout? A randomized clinical trial, J Clin Rheumatol, 21, 120, 10.1097/RHU.0000000000000235 · DOI
  104. Taylor, 2012, Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial, Am J Med, 125, 1126, 10.1016/j.amjmed.2012.05.025 · DOI
  105. Yamanaka, 2018, Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study, Ann Rheum Dis, 77, 270, 10.1136/annrheumdis-2017-211574 · DOI
  106. Borstad, 2004, Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis, J Rheumatol, 31, 2429
  107. Wortmann, 2010, Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials, Clin Ther, 32, 2386, 10.1016/j.clinthera.2011.01.008 · DOI
  108. Derksen, 2017, “What say ye gout experts?” a content analysis of questions about gout posted on the social news website Reddit, BMC Musculoskelet Disord, 18, 488, 10.1186/s12891-017-1856-y · DOI
  109. Juraschek, 2016, Effects of the dietary approaches to stop hypertension (DASH) diet and sodium intake on serum uric acid, Arthritis Rheumatol, 68, 3002, 10.1002/art.39813 · DOI
  110. Nielsen, 2017, Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies, Ann Rheum Dis, 76, 1870, 10.1136/annrheumdis-2017-211472 · DOI
  111. Dessein, 2000, Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study, Ann Rheum Dis, 59, 539, 10.1136/ard.59.7.539 · DOI · Paper page
  112. Neogi, 2014, Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study, Am J Med, 127, 311, 10.1016/j.amjmed.2013.12.019 · DOI
  113. Holland, 2015, Comprehensive dietary education in treated gout patients does not further improve serum urate, Intern Med J, 45, 189, 10.1111/imj.12661 · DOI
  114. Takahashi, 2003, Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism, Ann Rheum Dis, 62, 572, 10.1136/ard.62.6.572 · doi:10.1136/ard.62.6.572
  115. Stamp, 2017, A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout, Ann Rheum Dis, 76, 1522, 10.1136/annrheumdis-2016-210872 · DOI
  116. White, 2018, Cardiovascular safety of febuxostat or allopurinol in patients with gout, N Engl J Med, 378, 1200, 10.1056/NEJMoa1710895 · DOI · Paper page
  117. Gutiérrez-Macías, 2005, Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia, BMJ, 331, 623, 10.1136/bmj.331.7517.623 · doi:10.1136/bmj.331.7517.623
  118. Keller, 2018, Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study, Ann Rheum Dis, 77, 1187, 10.1136/annrheumdis-2017-212905 · DOI
  119. Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci USA, 102, 4134, 10.1073/pnas.0409500102 · DOI · Paper page
  120. Ko, 2015, Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study, BMJ, 351
  121. Stamp, 2012, Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol, Arthritis Rheum, 64, 2529, 10.1002/art.34488 · DOI · Paper page
  122. Wright, 2016, Predicting allopurinol response in patients with gout, Br J Clin Pharmacol, 81, 277, 10.1111/bcp.12799 · DOI
  123. Wright, 2018, The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool, Br J Clin Pharmacol, 84, 937, 10.1111/bcp.13516 · doi:10.1111/bcp.13516
  124. Mackenzie, 2020, Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial, Lancet, 396, 1745, 10.1016/S0140-6736(20)32234-0 · DOI · Paper page
  125. Reinders, 2009, A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout, Ann Rheum Dis, 68, 892, 10.1136/ard.2008.091462 · DOI
  126. Reinders, 2009, Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol, Ann Rheum Dis, 68, 51, 10.1136/ard.2007.083071 · DOI · Paper page
  127. Sundy, 2011, Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials, JAMA, 306, 711, 10.1001/jama.2011.1169 · DOI · Paper page
  128. Botson, 2020, Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR), J Rheumatol
  129. Waldman, 2018, Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study, Lancet Diabetes Endocrinol, 6, 310, 10.1016/S2213-8587(18)30029-9 · DOI
  130. Choi, 2012, Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study, BMJ, 344, 10.1136/bmj.d8190 · DOI · Paper page
  131. Li, 2019, The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program, Lancet Rheumatol, 1, E220, 10.1016/S2665-9913(19)30078-5 · DOI
  132. Maglio, 2017, Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial, Ann Rheum Dis, 76, 688, 10.1136/annrheumdis-2016-209958 · DOI
  133. Rai, 2017, The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study, BMJ, 357
  134. Kimura, 2018, Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial, Am J Kidney Dis, 72, 798, 10.1053/j.ajkd.2018.06.028 · DOI · Paper page
  135. Solomon, 2018, Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial, Ann Intern Med, 169, 535, 10.7326/M18-1167 · DOI
  136. Robinson, 2015, An observational study of gout prevalence and quality of care in a national Australian general practice population, J Rheumatol, 42, 1702, 10.3899/jrheum.150310 · DOI
  137. Proudman, 2019, Gout, flares, and allopurinol use: a population-based study, Arthritis Res Ther, 21, 132, 10.1186/s13075-019-1918-7 · doi:10.1186/s13075-019-1918-7
  138. Scheepers, 2018, Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD), Rheumatology (Oxford), 57, 1641, 10.1093/rheumatology/key155 · DOI
  139. Rai, 2018, Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies, Rheumatology (Oxford), 57, 1282, 10.1093/rheumatology/kex530 · DOI
  140. Rai, 2015, The economic burden of gout: A systematic review, Semin Arthritis Rheum, 45, 75, 10.1016/j.semarthrit.2015.02.004 · DOI
  141. Clarson, 2015, Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis, Eur J Prev Cardiol, 22, 335, 10.1177/2047487313514895 · DOI
  142. Porter, 1994, Gout: framing and fantasizing disease, Bull Hist Med, 68, 1
  143. Stamp, 2013, Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial, Arthritis Rheum, 65, 1636, 10.1002/art.37925 · DOI
  144. Stamp, 2020, Lack of effect of tart cherry concentrate dose on serum urate in people with gout, Rheumatology (Oxford), 59, 2374, 10.1093/rheumatology/kez606 · doi:10.1093/rheumatology/kez606
  145. Singh, 2014, Research priorities in gout: the patient perspective, J Rheumatol, 41, 615, 10.3899/jrheum.131258 · DOI
  146. Li, 2017, Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies, BMJ, 357
  147. Singh, 2018, Gout and dementia in the elderly: a cohort study of Medicare claims, BMC Geriatr, 18, 281, 10.1186/s12877-018-0975-0 · DOI
  148. Singh, 2019, Gout and the risk of Parkinson's disease in older adults: a study of US Medicare data, BMC Neurol, 19, 4, 10.1186/s12883-018-1234-x · DOI
  149. Mikuls, 2019, Adherence and outcomes with urate-lowering therapy: a site-randomized trial, Am J Med, 132, 354, 10.1016/j.amjmed.2018.11.011 · DOI
  150. Lawrence, 2019, Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach, J Prim Health Care, 11, 117, 10.1071/HC18082 · doi:10.1071/hc18082
  151. Fields, 2017, Pilot study of a multidisciplinary gout patient education and monitoring program, Semin Arthritis Rheum, 46, 601, 10.1016/j.semarthrit.2016.10.006 · DOI

Cited by

See all 1,338

Metadata

Authors
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-05
Volume
397
Issue
10287
Pages
1843-1855
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(21)00569-9
OpenAlex
W4239736175
Cited by
1,338
References
6
FWCI
103.21
Type
journal article
Language
en
Update notices
erratum (2021-05-15)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gout. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00569-9
The paper
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021). Gout. The Lancet. https://doi.org/10.1016/s0140-6736(21)00569-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.